Glenmark unveils details of its TRPA1 antagonist

 
• By Anju Ghangurde

Glenmark Pharmaceuticals is developing a TRPA1 receptor antagonist for pain and respiratory disorders.

More from Cardiovascular

More from Therapeutic Category